首页> 外文期刊>World Journal of Surgical Oncology >CT-guided percutaneous microwave ablation of pulmonary malignancies: Results in 69 cases
【24h】

CT-guided percutaneous microwave ablation of pulmonary malignancies: Results in 69 cases

机译:CT引导下经皮微波消融治疗肺部恶性肿瘤69例

获取原文
           

摘要

Background Microwave ablation (MWA) has attracted a worldwide attention gradually in treating inoperable pulmonary malignancies. However, in the lung tissues treated with MWA recurrence of tumor may still occur and few data in large patient groups till now were reported about the safety or effectiveness of microwave ablation in treating primary lung cancer and metastatic pulmonary malignancies. The purpose of this study is to evaluate the clinical curative effect (local control, survival data) MWA and its safety as well. Methods From 1 January 2005 to 1 January 2008, retrospective analyses, 69 patients underwent computed tomography (CT)-guided percutaneous MWA of pulmonary malignancies. All patients were deemed medically inoperable. The correlation of tumor sizes and local progression after ablation was analyzed and the survival rates within 3?years post surgery were compared between non-small-cell lung cancer and pulmonary metastases groups also. Results Pneumothorax was the most frequent complication and occurred in 24.64% patients after ablation. Neither needle track implantation was found nor did patient death occur in these patients within 30?days. The 1-, 2-, and 3-year overall survival rates were 66.7%, 44.9% and 24.6%, respectively. The overall survival rates for NSCLC patients in 1?year, 2?years, and 3?years were 75.0%, 54.2%, and 29.2%, respectively. The overall survival rates for pulmonary metastatic tumor patients in 1?year, 2?years, and 3?years were 47.6%, 23.8%, and 14.3%, respectively. The recurrence-free survival rates for NSCLC patients in 1?year, 2?years, and 3?years were 72.9%, 50.0%, and 27.1%, respectively. The mortality rates for pulmonary metastatic tumor patients in 1?year, 2?years, and 3?years were 47.6%, 19.0%, and 14.3%, respectively. Conclusions Percutaneous microwave coagulation therapy was one safe and effective method and could be beneficial for the improvement of inoperable pulmonary malignancies treatment effect.
机译:背景技术微波消融(MWA)在治疗无法手术的肺部恶性肿瘤方面已逐渐引起全球关注。然而,在用MWA治疗的肺组织中,肿瘤的复发仍可能发生,迄今为止,在大型患者组中尚无关于微波消融治疗原发性肺癌和转移性肺恶性肿瘤安全性或有效性的数据报道。这项研究的目的是评估MWA的临床疗效(局部控制,生存数据)及其安全性。方法2005年1月1日至2008年1月1日,对69例患者行计算机X线断层扫描(CT)指导的经皮MWA肺部恶性肿瘤检查。所有患者均被视为无法手术。分析了消融后肿瘤大小与局部进展的相关性,并比较了非小细胞肺癌和肺转移组术后3年内的生存率。结果气胸是最常见的并发症,发生在消融后占24.64%。这些患者在30天之内都没有发现针迹植入术,也没有发生患者死亡。 1年,2年和3年总生存率分别为66.7%,44.9%和24.6%。 NSCLC患者1年,2年和3年的总生存率分别为75.0%,54.2%和29.2%。肺转移性肿瘤患者1年,2年和3年的总生存率分别为47.6%,23.8%和14.3%。 NSCLC患者1年,2年和3年的无复发生存率分别为72.9%,50.0%和27.1%。肺转移性肿瘤患者在1年,2年和3年中的死亡率分别为47.6%,19.0%和14.3%。结论经皮微波凝集治疗是一种安全有效的方法,对改善不能手术的肺部恶性肿瘤的治疗效果是有利的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号